Rituximab in ANCA-associated vasculitis: a revolution?

被引：14
|
作者：
Tervaert, Jan Willem Cohen [1 ]
机构：
[1] Maastricht Univ Med Ctr, Dept Internal Med, Div Clin & Expt Immunol, Maastricht, Netherlands
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2011年 / 26卷 / 10期
关键词：
ANCA; pathophysiology; rituximab; therapy; ANTINEUTROPHIL CYTOPLASMIC AUTOANTIBODIES; WEGENERS-GRANULOMATOSIS; SYSTEMIC VASCULITIS; RENAL VASCULITIS; ANIMAL-MODEL; GLOMERULONEPHRITIS; CYCLOPHOSPHAMIDE; AAV; RTX; ACTIVATION;
D O I：
10.1093/ndt/gfr507
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
引用
收藏
页码：3077 / 3079
页数：3
相关论文
共 50 条
  • [21] Retreatment With Rituximab In The Rituximab In ANCA-Associated Vasculitis (RAVE) Trial
    Miloslavsky, Eli
    Specks, Ulrich
    Merkel, Peter A.
    Seo, Philip
    Spiera, Robert F.
    Langford, Carol A.
    Hoffman, Gary S.
    Kallenberg, Cees G. M.
    St Clair, E. William
    Tchao, Nadia
    Ding, Linna
    Ikle, David
    Jepson, Brett
    Brunetta, Paul
    Stone, John H.
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S1190 - S1190
  • [22] Impact of rituximab trials on the treatment of ANCA-associated vasculitis
    Alberici, Federico
    Jayne, David R. W.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 (06) : 1151 - 1159
  • [23] Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis
    Guillevin, L.
    Pagnoux, C.
    Karras, A.
    Khouatra, C.
    Aumaitre, O.
    Cohen, P.
    Maurier, F.
    Decaux, O.
    Ninet, J.
    Gobert, P.
    Quemeneur, T.
    Blanchard-Delaunay, C.
    Godmer, P.
    Puechal, X.
    Carron, P. -L.
    Hatron, P. -Y.
    Limal, N.
    Hamidou, M.
    Ducret, M.
    Daugas, E.
    Papo, T.
    Bonnotte, B.
    Mahr, A.
    Ravaud, P.
    Mouthon, L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (19): : 1771 - 1780
  • [24] Rituximab for ANCA-associated vasculitis: The experience in the United States
    Clain, Jeremy M.
    Specks, Ulrich
    PRESSE MEDICALE, 2013, 42 (04): : 530 - 532
  • [25] Long-term rituximab for ANCA-associated vasculitis
    Thorley, Jennifer
    LANCET RHEUMATOLOGY, 2020, 2 (07): : E389 - E389
  • [26] Rituximab for ANCA-associated vasculitis in the setting of severe infection
    Gregersen, J. W.
    Chaudhry, A.
    Jayne, D. R. W.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2013, 42 (03) : 207 - 210
  • [27] Rituximab in ANCA-associated vasculitis (AAV), a case series
    Wendt, Marten
    Gunnarsson, Iva
    Bratt, Johan
    Bruchfeld, Annette
    APMIS, 2009, 117 : 80 - 80
  • [28] Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis.
    Stone, John H.
    Merkel, Peter A.
    Spiera, Robert
    Seo, Philip
    Langford, Carol A.
    Hoffman, Gary S.
    Kallenberg, Cees G. M.
    Clair, E. William St.
    Turkiewicz, Anthony
    Tchao, Nadia K.
    Webber, Lisa
    Ding, Linna
    Sejismundo, Lourdes P.
    Mieras, Kathleen
    Weitzenkamp, David
    Ikle, David
    Seyfert-Margolis, Vicki
    Mueller, Mark
    Brunetta, Paul
    Allen, Nancy B.
    Fervenza, Fernando C.
    Geetha, Duvuru
    Keogh, Karina A.
    Kissin, Eugene Y.
    Monach, Paul A.
    Peikert, Tobias
    Stegeman, Coen
    Ytterberg, Steven R.
    Specks, Ulrich
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (03): : 221 - 232
  • [29] Maintenance rituximab treatment for ANCA-associated vasculitis: to be continued?
    Cheung, Chee Kay
    McAdoo, Stephen P.
    RHEUMATOLOGY, 2021, 60 (03) : 1010 - 1012
  • [30] ANCA Response upon Rituximab or Cyclophosphamide in ANCA-associated Vasculitis Patients
    van Dam, Laura
    Dirikgil, Ebru
    Bredewold, Edwin
    Ray, Argho
    Rabelink, Ton
    van Kooten, Cees
    Teng, Onno
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
12345